Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Accumulated Expenses (2016 - 2025)

Aptevo Therapeutics' Accumulated Expenses history spans 11 years, with the latest figure at $1.9 million for Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 106.18% year-over-year to $1.9 million; the TTM value through Sep 2025 reached $1.9 million, up 106.18%, while the annual FY2024 figure was $1.9 million, 11.53% down from the prior year.
  • Accumulated Expenses for Q3 2025 was $1.9 million at Aptevo Therapeutics, up from $1.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $2.1 million in Q4 2022 and bottomed at $472000.0 in Q1 2025.
  • The 5-year median for Accumulated Expenses is $1.4 million (2022), against an average of $1.4 million.
  • The largest annual shift saw Accumulated Expenses surged 156.78% in 2024 before it plummeted 70.68% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $2.1 million in 2021, then increased by 1.35% to $2.1 million in 2022, then decreased by 0.33% to $2.1 million in 2023, then fell by 11.53% to $1.9 million in 2024, then grew by 2.42% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for APVO's Accumulated Expenses are $1.9 million (Q3 2025), $1.0 million (Q2 2025), and $472000.0 (Q1 2025).